TY - JOUR T1 - Future treatment for asthma JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 77 LP - 92 DO - 10.1183/16000617.0069-2015 VL - 25 IS - 139 AU - Jeremy Charriot AU - Isabelle Vachier AU - Laurence Halimi AU - Anne-Sophie Gamez AU - Clement Boissin AU - Marine Salama AU - Alina Cucu-Jarjour AU - Engi Ahmed AU - Arnaud Bourdin Y1 - 2016/03/01 UR - http://err.ersjournals.com/content/25/139/77.abstract N2 - The landscape of asthma has considerably changed after 40 years of inhaled corticosteroid development and nearly 20 years since the first monoclonal antibodies (mAbs) were approved. New members of pharmacological families and more effective drug-delivery devices have been designed but the proportion of uncontrolled patients, unfortunately, remains stable. The most promising treatments now rely on targeted therapies that encourage the improvement of the characterisation of our patients. These clinical (phenotype) or new biological (endotype) tools lead to palpable personalised medicine. This review examines not only the future of mAbs and other new ways of treating asthma but also describes futuristic views based on the paradigm shifts that are ready to occur.Future treatment for asthma: easier, safer, personalised http://ow.ly/V7b4h ER -